{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:54:10Z","timestamp":1792061650637,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":2969,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chinese Medical Sciences Journal"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.24920\/21803","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T22:46:44Z","timestamp":1520462804000},"page":"9-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapy of Rituximab in Idiopathic Membranous Nephropathy with Nephrotic Syndrome: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"33","author":[{"given":"Peimei","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.24920\/21803_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJM199307083290203","article-title":"Prognosis of untreated patients with idiopathic membranous nephropathy","volume":"329","author":"Schieppati","year":"1993","journal-title":"N Engl J Med"},{"issue":"10","key":"10.24920\/21803_bib2","article-title":"Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome","author":"Chen","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.24920\/21803_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"10.24920\/21803_bib4","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1681\/ASN.2005010028","article-title":"Management of membranous nephropathy: when and what for treatment","volume":"16","author":"Cattran","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.24920\/21803_bib5","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1046\/j.1523-1755.2001.0590051983.x","article-title":"Idiopathic membranous glomerulonephritis","volume":"59","author":"Cattran","year":"2001","journal-title":"Kidney Int"},{"issue":"3","key":"10.24920\/21803_bib6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrneph.2012.289","article-title":"Rituximab therapy in nephrotic syndrome: implications for patients' management","volume":"9","author":"Sinha","year":"2013","journal-title":"Nat Rev Nephrol"},{"issue":"9337","key":"10.24920\/21803_bib7","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.24920\/21803_bib8","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"issue":"3","key":"10.24920\/21803_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000430849","article-title":"A multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (MENTOR)","volume":"130","author":"Fervenza","year":"2015","journal-title":"Nephron"},{"issue":"5","key":"10.24920\/21803_bib10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/ckj\/sfv075","article-title":"A European multicentre and open-label controlled randomized trial to evaluate the efficacy of sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study","volume":"8","author":"Rojas-Rivera","year":"2015","journal-title":"Clin Kidney J"},{"issue":"8","key":"10.24920\/21803_bib11","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.24920\/21803_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/ndt\/gfs379","article-title":"Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study","volume":"28","author":"Irazabal","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.24920\/21803_bib13","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2215\/CJN.06041108","article-title":"Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients","volume":"4","author":"Segarra","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.24920\/21803_bib14","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.24920\/21803_bib15","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.24920\/21803_bib16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1159\/000327611","article-title":"Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study","volume":"33","author":"Cravedi","year":"2011","journal-title":"Am J Nephrol"},{"issue":"12","key":"10.24920\/21803_bib17","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.24920\/21803_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"issue":"10","key":"10.24920\/21803_bib19","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/ndt\/gfw251","article-title":"Low-dose rituximab is poorly effective in patients with primary membranous nephropathy","volume":"32","author":"Moroni","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.24920\/21803_bib20","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1097\/01.ASN.0000071511.35221.B3","article-title":"Rituximab in idiopathic membranous nephropathy: a one-year prospective study","volume":"14","author":"Ruggenenti","year":"2003","journal-title":"J Am Soci Nephrol"},{"issue":"4","key":"10.24920\/21803_bib21","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2215\/CJN.01080905","article-title":"Rituximab for idiopathic membranous nephropathy: who can benefit?","volume":"1","author":"Ruggenenti","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.24920\/21803_bib22","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","article-title":"Idiopathic membranous nephropathy: definition and relevance of a partial remission","volume":"66","author":"Troyanov","year":"2004","journal-title":"Kidney Int"},{"issue":"4","key":"10.24920\/21803_bib23","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.24920\/21803_bib24","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.24920\/21803_bib25","first-page":"15","article-title":"Prognostic value of T lymphocyte subset ratio in idiopathic membranous nephropathy","volume":"8","author":"Zucchelli","year":"1988","journal-title":"Am J Nephrol"},{"issue":"10","key":"10.24920\/21803_bib26","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.24920\/21803_bib27","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.1993.292","article-title":"The increased risk of coronary heart disease associated with nephrotic syndrome","volume":"44","author":"Ordo\u00f1ez","year":"1993","journal-title":"Kidney International"},{"issue":"5","key":"10.24920\/21803_bib28","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.kint.2015.12.041","article-title":"Patients with primary membranous nephropathy are at high risk of cardiovascular events","volume":"89","author":"Lee","year":"2016","journal-title":"Kidney Int"},{"issue":"8","key":"10.24920\/21803_bib29","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1038\/sj.ki.5001790","article-title":"Membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association","volume":"70","author":"Lefaucheur","year":"2006","journal-title":"Kidney Int"},{"issue":"3","key":"10.24920\/21803_bib30","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2215\/CJN.04160413","article-title":"Glomerular diseases: membranous nephropathy\u2014a modern view","volume":"9","author":"Ponticelli","year":"2014","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Chinese Medical Sciences Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1001929418300178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1001929418300178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/cmsj.cams.cn\/previewFile?fileName=%E5%88%A9%E5%A6%A5%E6%98%94%E5%8D%95%E6%8A%97%E5%9C%A8%E7%89%B9%E5%8F%91%E6%80%A7%E8%86%9C%E6%80%A7%E8%82%BE%E7%97%85%E4%B8%AD%E7%9A%84%E6%B2%BB%E7%96%97&id=56213573&type=pdf&lang=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:31:44Z","timestamp":1792060304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1001929418300178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1001929418300178"],"URL":"https:\/\/doi.org\/10.24920\/21803","relation":{},"ISSN":["1001-9294"],"issn-type":[{"value":"1001-9294","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy of Rituximab in Idiopathic Membranous Nephropathy with Nephrotic Syndrome: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Chinese Medical Sciences Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.24920\/21803","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 Chinese Academy Medical Sciences. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}